Equillium, Inc. (NASDAQ:EQ) Stock Has Consensus Price Target of $7.57 According to Brokerages

Equillium, Inc. (NASDAQ:EQ) has received an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.57.

EQ has been the topic of a number of research reports. Piper Sandler started coverage on Equillium in a report on Monday, July 13th. They issued an “overweight” rating on the stock. Roth Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Equillium in a research note on Friday, September 4th. Zacks Research upgraded shares of Equillium from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Clear Str raised shares of Equillium to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th.

Institutional Investors Weigh In On Equillium

A number of large investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in shares of Equillium during the 2nd quarter valued at about $35,000. Coastal Bridge Advisors LLC acquired a new stake in Equillium in the 2nd quarter worth approximately $48,000. Dimensional Fund Advisors LP acquired a new stake in Equillium in the 1st quarter worth approximately $31,000. High Net Worth Advisory Group LLC bought a new stake in Equillium during the second quarter worth approximately $107,000. Finally, Jefferies Financial Group Inc. bought a new stake in Equillium during the second quarter worth approximately $109,000. 27.05% of the stock is currently owned by institutional investors.

Equillium Trading Down 5.2%

EQ opened at $1.54 on Tuesday. The stock has a fifty day moving average price of $2.15 and a 200 day moving average price of $2.33. Equillium has a 1 year low of $0.76 and a 1 year high of $3.54. The stock has a market cap of $97.65 million, a price-to-earnings ratio of -7.70 and a beta of 1.93.

Equillium (NASDAQ:EQ) last issued its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. As a group, sell-side analysts forecast that Equillium will post -0.21 earnings per share for the current fiscal year.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s research is based on modulating immune pathways involved in T-cell activation, inflammation and tissue damage.

Its lead investigational product is itolizumab, an anti-CD6 monoclonal antibody designed to regulate pathogenic T-cell activity. Equillium has evaluated itolizumab in immune-mediated conditions, including acute graft-versus-host disease and other inflammatory disorders.